Jihoon Chang

Title: Jihoon Chang: Innovator in Biotechnology

Introduction

Jihoon Chang is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of novel proteins and therapeutic agents. With a total of three patents to his name, Chang's work focuses on addressing critical health challenges through innovative solutions.

Latest Patents

Chang's latest patents include the development of detoxified and immunologically active proteins known as 'mutant LTs.' These proteins have mutated amino acid sequences of heat-labile enterotoxin and are designed for use as immunogenic antigens for vaccination. Unlike wild-type LT, the mutant LTs do not induce toxic activities, making them promising candidates for a novel diarrheal vaccine in humans and animals. Additionally, Chang has developed a nucleic acid encoding an angiogenesis inhibitor named LK68. This inhibitor shows potential as an anticancer agent and has demonstrated effectiveness in inhibiting tumor growth and angiogenesis.

Career Highlights

Jihoon Chang is affiliated with the Mogam Biotechnology Research Institute, where he conducts his research and development activities. His work has garnered attention for its potential applications in vaccine development and cancer treatment.

Collaborations

Chang collaborates with notable colleagues, including Jang Seong Kim and Eun Jeong Park, who contribute to his research endeavors.

Conclusion

Jihoon Chang's innovative work in biotechnology highlights his commitment to advancing health solutions through his patented inventions. His contributions have the potential to significantly impact vaccine development and cancer treatment strategies.